Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors

Journal of Molecular Graphics and Modelling

Volumn 23, Issue 4, 2005, Pages 317-328

  Yuan, Hongbin ^a   Parrill, Abby ^a  

^a University of Memphis   (United States)

Author keywords

Cluster analysis; Human immunodeficiency virus; Inhibition; Integrase; Quantitative structure activity relationship

Indexed keywords

CHEMICAL COMPOUNDS; DISEASES; INORGANIC ACIDS; MATHEMATICAL MODELS;

CLUSTER ANALYSIS; CLUSTERS; HIV; MOLECULAR FIELD ANALYSIS (MFA);

ENZYME INHIBITION;

1 (5 CHLOROINDOL 3 YL) 3 (TETRAZOLYL) 1,3 PROPANEDIONE ENOL; 3,3,3',3' TETRAMETHYL 1,1' SPIROBIS(INDAN) 5,5',6,6' TETROL; 4 ACETYLAMINO 5 HYDROXYNAPHTHALENE 2,7 DISULFONIC ACID; AROMATIC AMIDE; CICHORIC ACID; COUMARIN; CURCUMIN; DEPSIDONE; HYDRAZINE DERIVATIVE; INTEGRASE INHIBITOR; KETONE DERIVATIVE; QUINALIZARIN; QUINOLINE DERIVATIVE; SALICYLHYDRAZINE; STYRYLQUINOLINE; SULFONAMIDE; TETRACYCLINE; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTICLE; CLUSTER ANALYSIS; DRUG BINDING SITE; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CLUSTER ANALYSIS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 12844275037     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2004.10.003     Document Type: Article

References (42)

1. E. De Clercq Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections J. Med. Chem. 38 1995 2491 2517
2. W.E.J. Robinson HIV integrase: the next target? Infect. Med. 15 1998 129 137
3. N. Neamati Structure-based HIV-1 integrase inhibitor design: a future perspective Expert Opin. Invest. Drugs 10 2001 281 296
4. S.D. Young Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics Curr. Opin. Drug Discov. Dev. 4 2001 402 410
5. I.J. Chen, N. Neamati, and A.D. MacKerell Jr. Structure-based inhibitor design targeting HIV-1 integrase Curr. Drug Targets Infect. Disord. 2 2002 217 234
6. N. Neamati, Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga, Expert Opin. Ther. Patents 12 (2002) 709-724.
7. A.L. Parrill HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives Curr. Med. Chem. 10 2003 1811 1824
8. C. Hansch A quantitative approach to biochemical structure-activity relationships Acc. Chem. Res. 2 1969 232 239
9. A.R. Katritzky, and E.V. Gordeeva Traditional topological indices vs. electronic geometrical and combined molecular descriptors in QSAR/QSPR research J. Chem. Inf. Comput. Sci. 33 1993 835 857
10. H. Van de Waterbeemd Recent progress in QSAR-technology Drug Des. Discov. 9 1993 277 285
11. R.D. Cramer III, D.E. Patterson, and J.D. Bunce Comparative molecular field analysis (CoMFA). Part 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 110 1998 5959 5967
12. C. Marchand, X. Zhang, G.C. Pais, K. Cowansage, N. Neamati, T.R. Burke Jr., and Y. Pommier Structural determinants for HIV-1 integrase inhibition by beta-diketo acids J. Biol. Chem. 277 2002 12596 12603
13. Y. Goldgur, R. Craigie, G.H. Cohen, T. Fujiwara, T. Yoshinaga, T. Fujishita, H. Sugimoto, T. Endo, H. Murai, and D.R. Davies Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design Proc. Natl. Acad. Sci. U.S.A. 96 1999 13040 13043
14. J. Lubkowski, F. Yang, J. Alexandratos, A. Wlodawer, H. Zhao, T.R. Burke Jr., N. Neamati, Y. Pommier, G. Merkel, and A.M. Skalka Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor Proc. Natl. Acad. Sci. U.S.A. 95 1998 4831 4836
15. V. Molteni, J. Greenwald, D. Rhodes, Y. Hwang, W. Kwiatkowski, F.D. Bushman, J.S. Siegel, and S. Choe Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain Acta Crystallogr. D Biol. Crystallogr. 57 2001 536 544
16. H. Yuan, and A.L. Parrill QSAR studies of HIV-1 integrase inhibition Bioorg. Med. Chem. 10 2002 4169 4183
17. M.T. Makhija, and V.M. Kulkarni QSAR of HIV-1 integrase inhibitors by genetic function approximation method Bioorg. Med. Chem. 10 2002 1483 1497
18. C.A. Sotriffer, H. Ni, and J.A. McCammon Active site binding modes of HIV-1 integrase inhibitors J. Med. Chem. 43 2000 4109 4117
19. J.A. Grobler, K. Stillmock, B. Hu, M. Witmer, P. Felock, A.S. Espeseth, A. Wolfe, M. Egbertson, M. Bourgeois, J. Melamed, J.S. Wai, S. Young, J. Vacca, and D.J. Hazuda Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes Proc. Natl. Acad. Sci. U.S.A. 99 2002 6661 6666
20. K. Zhu, M.L. Cordeiro, J. Atienza, W.E. Robinson Jr., and S.A. Chow Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids J. Virol. 73 1999 3309 3316
21. A.S. Espeseth, P. Felock, A. Wolfe, M. Witmer, J. Grobler, N. Anthony, M. Egbertson, J.Y. Melamed, S. Young, T. Hamill, J.L. Cole, and D.J. Hazuda HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase Proc. Natl. Acad. Sci. U.S.A. 97 2000 11244 11249
22. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comp. Chem. 19 1998 1639 1662
23. Cerius2 Program, Molecular Simulations Inc., 1999.
24. MOE Program, Chemical Computing Group Inc., 2002.
25. D.M. Ferguson, and D.J. Raber A new approach to probing conformational space with molecular mechanics: random incremental pulse search J. Am. Chem. Soc. 111 1989 4371 4378
26. T.A. Halgren Merck molecular force field. Part I. Basis, form, scope, parameterization, and performance of MMFF94* J. Comp. Chem. 17 1996 490 519
27. D. Rogers, and A.J. Hopfinger Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships J. Chem. Inf. Comput. Sci. 34 1994 854 866
28. K. Raghavan, J.K. Buolamwini, M.R. Fesen, Y. Pommier, K.W. Kohn, and J.N. Weinstein Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study J. Med. Chem. 38 1995 890 897
29. J.K. Buolamwini, and H. Assefa CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site J. Med. Chem. 45 2002 841 852
30. A. Mazumder, A. Gazit, A. Levitzki, M. Nicklaus, J. Yung, G. Kohlhagen, and Y. Pommier Effect of tyrphostins, protein kinase inhibitors, on Human immunodeficiency virus type 1 integrase Biochemistry 35 1995 15111 15122
31. H. Zhao, N. Neamati, H. Hong, A. Mazumder, S. Wang, S. Sunder, G.W. Milne, Y. Pommier, and T.R. Burke Jr. Coumarin-based inhibitors of HIV integrase J. Med. Chem. 40 1997 242 249
32. Z. Lin, N. Neamati, H. Zhao, Y. Kiryu, J.A. Turpin, C. Aberham, K. Strebel, K. Kohn, M. Witvrouw, C. Pannecouque, Z. Debyser, E. De Clercq, W.G. Rice, Y. Pommier, and T.R. Burke Jr. Chicoric acid analogues as HIV-1 integrase inhibitors J. Med. Chem. 42 1999 1401 1414
33. M.C. Nicklaus, N. Neamati, H. Hong, A. Mazumder, S. Sunder, J. Chen, G.W. Milne, and Y. Pommier HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching J. Med. Chem. 40 1997 920 929
34. N. Neamati, H. Hong, S. Sunder, G.W.A. Milne, and Y. Pommier Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors Mol. Pharmacol. 52 1997 1041 1055
35. H. Zhao, N. Neamati, A. Mazumder, S. Sunder, Y. Pommier, and T.R. Burke Jr. Arylamide inhibitors of HIV-1 integrase J. Med. Chem. 40 1997 1186 1194
36. N. Neamati, J.A. Turpin, H.E. Winslow, J.L. Christensen, K. Williamson, A. Orr, W.G. Rice, Y. Pommier, A. Garofalo, A. Brizzi, G. Campiani, I. Fiorini, and V. Nacci Thiazolothiazepine inhibitors of HIV-1 integrase J. Med. Chem. 42 1999 3334 3341
37. A. Mazumder, N. Neamati, S. Sunder, J. Schulz, H. Pertz, E. Eich, and Y. Pommier Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action J. Med. Chem. 40 1997 3057 3063
38. F. Zouhiri, J.F. Mouscadet, K. Mekouar, D. Desmaele, D. Savoure, H. Leh, F. Subra, M. Le Bret, C. Auclair, and J. d'Angelo Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture J. Med. Chem. 43 2000 1533 1540
39. N. Neamati, H. Hong, J.M. Owen, S. Sunder, H.E. Winslow, J.L. Christensen, H. Zhao, T.R. Burke Jr., G.W. Milne, and Y. Pommier Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site J. Med. Chem. 41 1998 3202 3209
40. N. Neamati, H. Hong, A. Mazumder, S. Wang, S. Sunder, M.C. Nicklaus, G.W. Milne, B. Proksa, and Y. Pommier Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching J. Med. Chem. 40 1997 942 951
41. C.M. Farnet, B. Wang, J.R. Lipford, and F.D. Bushman Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules Proc. Natl. Acad. Sci. U.S.A. 93 1996 9742 9747
42. V. Molteni, D. Rhodes, K. Rubins, M. Hansen, F.D. Bushman, and J.S. Siegel A new class of HIV-1 integrase inhibitors: the 3,3,3′ 3′-tetramethyl-11′-spirobi(indan)-5,5′,6,6′-tetrol family J. Med. Chem. 43 2000 2031 2039